0001209191-20-051504.txt : 20200922
0001209191-20-051504.hdr.sgml : 20200922
20200922171019
ACCESSION NUMBER: 0001209191-20-051504
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200918
FILED AS OF DATE: 20200922
DATE AS OF CHANGE: 20200922
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nashat Amir
CENTRAL INDEX KEY: 0001575843
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39512
FILM NUMBER: 201190198
MAIL ADDRESS:
STREET 1: 10835 ROAD TO THE CURE
STREET 2: SUITE 205
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Metacrine, Inc.
CENTRAL INDEX KEY: 0001634379
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472297384
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-369-7800
MAIL ADDRESS:
STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-18
0
0001634379
Metacrine, Inc.
MTCR
0001575843
Nashat Amir
C/O METACRINE, INC.
3985 SORRENTO VALLEY BLVD., SUITE C
SAN DIEGO
CA
92121
1
0
1
0
Common Stock
2020-09-18
4
P
0
214962
13.00
A
214962
I
See footnote
Common Stock
2020-09-18
4
P
0
15038
13.00
A
15038
I
See footnote
Common Stock
2020-09-18
4
C
0
1832582
A
2047544
I
See footnote
Common Stock
2020-09-18
4
C
0
128201
A
143239
I
See footnote
Common Stock
2020-09-18
4
C
0
451666
A
2499210
I
See footnote
Common Stock
2020-09-18
4
C
0
20585
A
163824
I
See footnote
Common Stock
2020-09-18
4
C
0
216106
A
2715316
I
See footnote
Common Stock
2020-09-18
4
C
0
15118
A
178942
I
See footnote
Series A Convertible Preferred Stock
2020-09-18
4
C
0
1832582
D
Common Stock
1832582
0
I
See footnote
Series A Convertible Preferred Stock
2020-09-18
4
C
0
128201
D
Common Stock
128201
0
I
See footnote
Series B Convertible Preferred Stock
2020-09-18
4
C
0
451666
D
Common Stock
451666
0
I
See footnote
Series B Convertible Preferred Stock
2020-09-18
4
C
0
20585
D
Common Stock
20585
0
I
See footnote
Series C Convertible Preferred Stock
2020-09-18
4
C
0
216106
D
Common Stock
216106
0
I
See footnote
Series C Convertible Preferred Stock
2020-09-18
4
C
0
15118
D
Common Stock
15118
0
I
See footnote
The reportable securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of the Reporting Person, a member of the Issuer's Board of Directors, David Barrett ("Barrett"), Brian Chee ("Chee") and Bryce Youngren ("Youngren" and, together with the Reporting Person, Barrett and Chee, the "Managing Members") are the managing members of PMC VII.
(continued from Footnote 2) Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PP VII. Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
The reportable securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PEF VII.
(continued from Footnote 3) Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
/s/ Lauren Crockett, Attorney-in-fact for Amir Nashat
2020-09-22